Growing adoption of Levofloxacin for treating bacterial infections is expected to drive the growth of India levofloxacin market during the forecast period.
According to TechSci Research report, “India Levofloxacin Market By Strength (250 mg Tablets, 500 mg Tablets, 750 mg Tablets), By Application (Pneumonia, Skin Infection, Kidney Infection, Bladder Infection, Others), By Form (Tablet, Capsule, Injection), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India Levofloxacin market is expected to grow at a steady pace during the forecast period owing to rise in the cases of bacterial infectious diseases. Continuous research in applications of levofloxacin by major market players coupled with involvement of international organizations is another major factor which is expected to fuel the market growth through FY2026. Levofloxacin is primarily used in skin infections as it is indicated for the treatment of complicated skin and skin structure infections caused by Enterococcus faecalis, methicillin-susceptible Staphylococcus aureus (MRSA), Streptococcus pyogenes, or Proteus mirabilis and others. However, side effects caused due to drug consumption including nausea, seizures, and diarrhea can restrict the market growth over the next few years. lack of awareness associated with infectious disease among the population might act as a major impediment to the market growth in the coming years.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Levofloxacin Market”
https://www.techsciresearch.com/report/india-levofloxacin-market/7199.html
The India levofloxacin market is segmented based on strength, application, form, route of administration, source, distribution channel, end user, company, and region. Based on application, the market can be categorized into pneumonia, skin infection, kidney infection, bladder infection, other. The pneumonia segment dominated the market until FY2020 and is forecasted to maintain its lead over the coming years as well. Rising incidence of pneumococcal disease is a high impact rendering driver. Furthermore, there has been a considerable increase in the number of community-acquired and ventilator-associated bacterial pneumonia, which is further estimated to boost the segmental growth. Based on end user, the market can be fragmented into adult v/s pediatric. Adult end user segment dominated the market until FY2020 and is expected to maintain its dominance in the market during forecasted years as well on account of high incidence of bacterial infections in adults.
Dr. Reddy’s Laboratories Ltd., Aden Healthcare Pvt. Ltd., Allenge India Pharmaceuticals Pvt. Ltd., Alna Biotech Pvt. Ltd., Bestochem Formulations India Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Cadila Healthcare Ltd., Valentis Pharma Pvt. Ltd., Pax Healthcare Pvt. Ltd. and others are some of the leading players operating in India levofloxacin market. Companies operating in the market are using organic strategies such as product launches, mergers and acquisitions and research collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7199
Customers can also request for 10% free customization on this report.
“India levofloxacin market is expected to witness growth in the next 5 years which can be attributed to the use of this drug for the diagnosis of pneumonia, urinary tract infection, acute bacterial sinusitis, chronic prostatitis, and others. In addition to this, increased count of skin and bacterial infections among the population is further expected to create lucrative opportunities for the market growth of India levofloxacin market over the next five years. Emergence of multi-drug resistant pathogens is further forecasted to aid the growth of levofloxacin market over the forthcoming years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“India Levofloxacin Market By Strength (250 mg Tablets, 500 mg Tablets, 750 mg Tablets), By Application (Pneumonia, Skin Infection, Kidney Infection, Bladder Infection, Others), By Form (Tablet, Capsule, Injection), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India levofloxacin market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India levofloxacin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]